In both types of lung cancer, somatic mutations contribute to the inhibition of growth suppressors, promotion of immune escape, and activation of various oncogenes, particularly epidermal growth factor receptor (EGFR) mutations in non-smokers [5]. The gene discussed is EGFR; the disease is lung cancer.